Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 466 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR This Bar of Soap with a Lump Will Help You Remember... May 31, 2019 The new home for your research tools April 11, 2022 Advancing Cancer Research as a Married Couple: “Your Stories” Podcast December 18, 2020 Why it’s difficult to estimate the number of extra cancer deaths... July 21, 2020 Load more HOT NEWS First treatment approved in England for advanced bile duct cancer GreaterGood’s Mask Donations Are Helping LA Family Housing Keep Homeless People... Born Blind With 50% Chance Of Survival, 20-Year-Old Musician Defied All... Promising Results Demostrated with Novel Subcutaneously Adminstered Envafolimab in Patients with...
